Nov 2, 4:05 PM ET
Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, representing a 12% increase compared to the same period in 2025, driven by cystic fibrosis therapies and newer product growth. The company raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion following strong performance and the closing of the Crinetics Pharmaceuticals acquisition. GAAP net income declined year-over-year to $654 million due to acquisition-related expenses.
- Total revenue for the third quarter of 2026 reached $3.44 billion, up 12% year-over-year.
- Full-year 2026 revenue guidance was raised to a range of $13.15 billion to $13.25 billion.
- GAAP net income was $654 million for the third quarter of 2026, compared to $1.1 billion in the third quarter of 2025.
- The acquisition of Crinetics Pharmaceuticals closed on September 1, 2026.
Read the filing on SEC.gov ↗
Oct 20, 4:09 PM ET
Vertex Pharmaceuticals appointed Daniel Brennan, a former Chief Financial Officer of Boston Scientific, to its board of directors on October 20, 2026, and expanded the board from ten to eleven members. He also joined the Audit and Finance Committee and received a $400,000 restricted stock unit award that vests in October 2027.
- Daniel Brennan joined the board on October 20, 2026; board size increased from ten to eleven members.
- Brennan retired in June 2025 as Executive Vice President and Chief Financial Officer of Boston Scientific, a role he held from January 2014.
- Brennan received a $400,000 restricted stock unit award vesting in October 2027 and joined the Audit and Finance Committee.
- The filing reports no related-person transactions requiring disclosure and no arrangement under which Brennan was appointed.
Read the filing on SEC.gov ↗
Sep 1, 4:25 PM ET
Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer on August 27, 2026, effective January 1, 2027. Charles F. Wagner, Jr. will stop serving as CFO on that date but will remain Executive Vice President and Chief Operating Officer. The filing discloses Mr. Poole's salary, bonus target and severance terms, which shareholders may review in the 10-Q exhibits later.
- Jonathan Poole, 51, becomes EVP and CFO effective January 1, 2027, having been Senior Vice President, Finance at Vertex since March 2020
- Charles F. Wagner, Jr. ceases to be CFO on the effective date and remains EVP and Chief Operating Officer
- Poole's base salary is $750,000, with a target annual bonus of 90% of base salary
- Severance on termination without cause or for good reason is 100% of base salary and target bonus; the change of control agreement covers the period from 90 days before to 12 months after a change of control
Read the filing on SEC.gov ↗
Aug 3, 4:09 PM ET
Vertex reported second quarter 2026 results on August 3, 2026, with total revenue of $3.33 billion, up 12% from the prior-year quarter, and GAAP net income of $1.1 billion. The company raised its full-year 2026 total revenue guidance, and it also announced a pending acquisition of Crinetics Pharmaceuticals for $85.00 per share in cash, expected to close in the third quarter of 2026, which is not reflected in its guidance.
- Q2 2026 total revenue was $3.33 billion, up from $2.96 billion in Q2 2025; GAAP net income was $1.10 billion, up from $1.03 billion.
- GAAP diluted earnings per share were $4.31, compared with $3.99 a year earlier.
- Full-year 2026 total revenue guidance was raised to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion.
- Vertex will acquire Crinetics for $85.00 per share in cash, a total equity value of about $10.0 billion, with closing expected in the third quarter of 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.